Clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease according to their epitopes

被引:2
作者
Seok, Jin Myoung [1 ]
Jeon, Mi Young [2 ]
Chung, Yeon Hak [2 ,3 ]
Ju, Hyunjin [2 ,3 ]
Lee, Hye Lim [4 ]
Kwon, Soonwook [5 ]
Min, Ju-Hong [2 ,3 ,6 ]
Kang, Eun-Suk [7 ]
Kim, Byoung Joon [2 ,3 ]
机构
[1] Soonchunhyang Univ, Soonchunhyang Univ Hosp Cheonan, Dept Neurol, Coll Med, Cheonan, South Korea
[2] Samsung Med Ctr, Neurosci Ctr, Dept Neurol, Seoul, South Korea
[3] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurol, Sch Med, Seoul, South Korea
[4] Korea Univ, Coll Med, Dept Neurol, Guro Hosp, Seoul, South Korea
[5] Inha Univ Hosp, Dept Neurol, Incheon, South Korea
[6] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea
[7] Sungkyunkwan Univ, Samsung Med Ctr, Dept Lab Med & Genet, Sch Med, Seoul, South Korea
来源
FRONTIERS IN NEUROLOGY | 2023年 / 14卷
基金
新加坡国家研究基金会;
关键词
central nervous system demyelinating diseases; myelin oligodendrocyte glycoprotein; autoantibodies; epitopes; immunoassay; MOG; SPECTRUM;
D O I
10.3389/fneur.2023.1200961
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundThe detection of myelin oligodendrocyte glycoprotein autoantibodies (MOG-Ab) is essential for the diagnosis of MOG-Ab-associated disease (MOGAD). The clinical implications of different epitopes recognized by MOG-Ab are largely unknown. In this study, we established an in-house cell-based immunoassay for detecting MOG-Ab epitopes and examined the clinical characteristics of patients with MOG-Ab according to their epitopes. MethodsWe conducted a retrospective review of patients with MOG-Ab-associated disease (MOGAD) in our single center registry, and collected serum samples from enrolled patients. Human MOG variants were generated to detect epitopes recognized by MOG-Ab. The differences in clinical characteristics according to the presence of reactivity to MOG Proline42 (P42) were evaluated. ResultsFifty five patients with MOGAD were enrolled. Optic neuritis was the most common presenting syndrome. The P42 position of MOG was a major epitope of MOG-Ab. The patients with a monophasic clinical course and childhood-onset patients were only observed in the group that showed reactivity to the P42 epitope. ConclusionWe developed an in-house cell-based immunoassay to analyze the epitopes of MOG-Ab. The P42 position of MOG is the primary target of MOG-Ab in Korean patients with MOGAD. Further studies are needed to determine the predictive value of MOG-Ab and its epitopes.
引用
收藏
页数:7
相关论文
共 29 条
  • [1] Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder
    Akaishi, Tetsuya
    Takahashi, Toshiyuki
    Misu, Tatsuro
    Kaneko, Kimihiko
    Takai, Yoshiki
    Nishiyama, Shuhei
    Ogawa, Ryo
    Fujimori, Juichi
    Ishii, Tadashi
    Aoki, Masashi
    Fujihara, Kazuo
    Nakashima, Ichiro
    [J]. NEUROLOGY, 2021, 97 (01) : E1 - E12
  • [3] Demyelinating myelin oligodendrocyte glycoprotein-specific autoantibody response is focused on one dominant conformational epitope region in rodents
    Breithaupt, Constanze
    Schaefer, Beatrix
    Pellkofer, Hannah
    Huber, Robert
    Linington, Christopher
    Jacob, Uwe
    [J]. JOURNAL OF IMMUNOLOGY, 2008, 181 (02) : 1255 - 1263
  • [4] Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
    Cobo-Calvo, Alvaro
    Ruiz, Anne
    Rollot, Fabien
    Arrambide, Georgina
    Deschamps, Romain
    Maillart, Elisabeth
    Papeix, Caroline
    Audoin, Bertrand
    Lepine, Anne Fabienne
    Maurey, Helene
    Zephir, Helene
    Biotti, Damien
    Ciron, Jonathan
    Durand-Dubief, Francoise
    Collongues, Nicolas
    Ayrignac, Xavier
    Labauge, Pierre
    Meyer, Pierre
    Thouvenot, Eric
    Bourre, Bertrand
    Montcuquet, Alexis
    Cohen, Mikael
    Horello, Philippe
    Tintore, Mar
    De Seze, Jerome
    Vukusic, Sandra
    Deiva, Kumaran
    Marignier, Romain
    [J]. ANNALS OF NEUROLOGY, 2021, 89 (01) : 30 - 41
  • [5] Cobo-Calvo A, 2019, J NEUROL, V266, P806, DOI 10.1007/s00415-018-9160-9
  • [6] The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults
    de Mol, C. L.
    Wong, Y. Y. M.
    van Pelt, E. D.
    Wokke, B. H. A.
    Siepman, T. A. M.
    Neuteboom, R. F.
    Hamann, D.
    Hintzen, R. Q.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (07) : 806 - 814
  • [7] Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria
    Fadda, Giulia
    Waters, Patrick
    Woodhall, Mark
    Brown, Robert A.
    O'Mahony, Julia
    Castro, Denise A.
    Longoni, Giulia
    Yeh, E. Ann
    Marrie, Ruth Ann
    Arnold, Douglas L.
    Banwell, Brenda
    Bar-Or, Amit
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (11) : 1697 - 1709
  • [8] Gardinier M V, 1993, Schweiz Arch Neurol Psychiatr (1985), V144, P201
  • [9] No strong HLA association with MOG antibody disease in the UK population
    Grant-Peters, Melissa
    Passos, Giordani Rodrigues Dos
    Yeung, Hing-Yuen
    Jacob, Anu
    Huda, Saif
    Leite, Maria Isabel
    Dendrou, Calliope A.
    Palace, Jacqueline
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2021, 8 (07): : 1502 - 1507
  • [10] What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients
    Hamid, Shahd H. M.
    Whittam, Daniel
    Mutch, Kerry
    Linaker, Samantha
    Solomon, Tom
    Das, Kumar
    Bhojak, Maneesh
    Jacob, Anu
    [J]. JOURNAL OF NEUROLOGY, 2017, 264 (10) : 2088 - 2094